Abstracts Archive - Page 2199 of 2605 - ACR Meeting Abstracts

Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Abstract Number: 479 • 2014 ACR/ARHP Annual Meeting
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years
Rene Westhovens¹, Edward C. Keystone², Clifton O. Bingham III³, Elizabeth C. Hsia^4,5, Lilianne Kim⁴, Yiying Zhou⁴, Alan M. Mendelsohn⁶ and Michael E. Weinblatt⁷, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years Background/Purpose: To describe the safety profile…
Abstract Number: 498 • 2014 ACR/ARHP Annual Meeting
Patient Experience with Initiation of SQ and Oral MTX
Jeffrey R. Curtis¹, David Mackey², Noam Gerber³, Aseem Bharat¹, Lang Chen⁴, Fenglong Xie⁵, Ben Nowell³, Kenneth G. Saag⁶ and Seth Ginsberg⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Creaky Joints/Global Healthy Living Foundation, Upper Nyack, NY, ⁴Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷CreakyJoints/Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose Methotrexate is the anchor drug used for the treatment of rheumatoid arthritis (RA). Despite its prominent position in RA therapeutics, its real-world effectiveness may…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 496 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study
Takashi Nakanishi¹, Hideyuki Horikoshi¹, Reiko Takahashi¹, Kanami Tongu², Junko Nishioka², Fumihiko Kimura³, Yuichi Nishioka² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²Nishioka Clinic for Rheumatic Diseases and Allergic Diseases, Kofu, Japan, ³National Defense Medical College, Tokorozawa, Japan
Background/Purpose Additional administration of low-dose tacrolimus (LD-TAC) at 0.5–1.0 mg daily was reported to be quite effective for rheumatoid arthritis (RA) patients with inadequate response…
Abstract Number: 495 • 2014 ACR/ARHP Annual Meeting
Discontinuation of Biologics in Patients with Rheumatoid Arthritis after Achieving Low-Activity Disease Status
Moeko Ochiai¹, Eri Sato¹, Eiichi Tanaka¹, Eisuke Inoue¹, Ayako Nakajima¹, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka², ¹Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Several clinical trials have reported bio-free remission or discontinuation of biologic DMARDs; however, these findings have not been confirmed in a real-world setting. The…
Abstract Number: 494 • 2014 ACR/ARHP Annual Meeting
Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Chia-Chen Teng², Tao He², Jianwei Leng³, Chao-Chin Lu², Derek Tang⁴, Neel Shah⁵, David J. Harrison⁴ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ⁴Amgen Inc., Thousand Oaks, CA, ⁵1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA
Background/Purpose: An algorithm based on administrative claims data (in lieu of clinical measures) was validated using data from the Veteran’s Affairs (VA) Rheumatoid Arthritis (RA)…
Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
C. Charles-Schoeman¹, Gerd Burmester², P. Nash³, C.a.F. Zerbini⁴, S. Anway⁵, K. Kwok⁶, T. Hendrikx⁷, E. Bananis⁸ and Roy Fleischmann⁹, ¹University of California, Los Angeles, CA, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer BV, Capelle aan den IJssel, Netherlands, ⁸Pfizer Inc, Collegeville, PA, ⁹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…
Abstract Number: 492 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept
J. Carter Thorne¹, Edward C. Keystone², Janet E. Pope³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁵ and Boulos Haraoui⁶, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The Canadian Methotrexate and Etanercept Outcome Study (CAMEO) evaluated etanercept (ETN) monotherapy vs ETN plus methotrexate (MTX) in biologic-naïve patients with rheumatoid arthritis…
Abstract Number: 491 • 2014 ACR/ARHP Annual Meeting
Do Patients with Congestive Heart Failure Treated with Biologics for RA Have a Lower Risk of Fatal Outcome of Serious Infections?
Anja Strangfeld¹, Adrian Richter¹, Yvette Meissner¹, Matthias Schneider², Michael Zaenker³, Wolfgang Ochs⁴, Thomas Klopsch⁵, Angela Zink⁶ and Joachim Listing¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ³Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany, ⁴Rheumatologist in private practice, Bayreuth, Germany, ⁵Rheumatologist in private practice, Neubrandenburg, Germany, ⁶German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Patients with multimorbid conditions are at high risk of developing serious infections (SI) and of premature mortality. TNF inhibitors increase the infection risk (1)…
Abstract Number: 490 • 2014 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis â€“ an Interim Analysis
Stephen Oakley^1,2,3, Niloofar Esmaili⁴, Gabor Major⁴, David Mathers^4,5, Siva Ratnarajah⁶, John van der Kallen⁵, Mark Collins⁶, Marc Toh⁶ and John Glass⁴, ¹Dept of Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Clinical Trials Unit, Hunter Medical Research Institute, Newcastle, Australia, ⁴Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ⁵Rheumatology, Georgetown Arthritis Centre, Newcastle, Australia, ⁶Rheumatology, Private Practice, Newcastle, Australia
Background/Purpose Rheumatoid arthritis (RA) is associated with elevated cardiovascular (CV) risk not explained by traditional risk factors. Increased CV risk may develop prior to the…
Abstract Number: 488 • 2014 ACR/ARHP Annual Meeting
Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Joel M. Kremer¹, Mark C Genovese², Edward C. Keystone³, Peter C. Taylor⁴, Steven H. Zuckerman⁵, Douglas E. Schlichting⁵, Eric P. Nantz⁵, Scott D. Beattie⁵ and William L. Macias⁶, ¹Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³University of Toronto, Toronto, ON, Canada, ⁴NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Treatment with baricitinib (bari), an oral inhibitor of JAK1/JAK2, demonstrated improvements in signs and symptoms of RA through 52 wks in a Phase 2b…
Abstract Number: 489 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases
Eirik Ikdahl¹, Silvia Rollefstad¹, Jonny Hisdal², Inge C. Olsen³, Ingar Holme⁴, Terje R. Pedersen⁵, Tore Kvien⁶ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, ⁵Faculty of Medicine, University of Oslo, Oslo, Norway, ⁶Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Arterial stiffness, as pulse wave velocity (PWV) and augmentation index (AIx) has emerged as early risk markers of cardiovascular disease (CVD) in patients with…
Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
C. Charles-Schoeman¹, A. Dikranian², J. Taylor³, B. Wilkinson⁴, T. Jones⁵, K. Kwok⁶ and C. Nduaka⁴, ¹University of California, Los Angeles, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Anderson Arthritis and Rheumatology Center, Meridian, MS, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
Abstract Number: 486 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Improves Arterial Stiffness Despite up-Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada², Toshikatsu Kanazawa³, Hiroshi Komori⁴, Kazuhiko Hatta⁵, Kuniki Amano⁶ and Noriko Kuwaba⁷, ¹20-16 Higashi Kannon, Nishi Ward, hiroshima clinic, Hiroshima, Japan, ²Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴internal medicine, hiroshima clinic, hiroshima, Japan, ⁵Rheumatology, Hatta Clinic, Kure, Japan, ⁶Rheumatology, Sky Clinic, Hiroshima, Japan, ⁷Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascularprevention in RA. Tofacitinib (Tofa) could possibly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].